Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/27/23
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor ConferenceGlobeNewsWire • 04/25/23
Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trialMarket Watch • 04/24/23
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual MeetinGlobeNewsWire • 04/10/23
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry MeetingGlobeNewsWire • 04/06/23
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/09/23
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate UpdateGlobeNewsWire • 03/09/23
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual MeetingGlobeNewsWire • 12/05/22
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/22/22
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual MeetingGlobeNewsWire • 11/09/22
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate UpdateGlobeNewsWire • 11/08/22
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of DirectorsGlobeNewsWire • 10/27/22
Can Foghorn Therapeutics Inc. (FHTX) Climb 161% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 10/26/22
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP ProgramGlobeNewsWire • 10/26/22
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation SummitGlobeNewsWire • 10/20/22
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology ConferenceGlobeNewsWire • 09/27/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Foghorn Therapeutics Inc. - FHTXNewsfile Corp • 09/18/22
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDSGlobeNewsWire • 08/23/22